Santa Clara, CA. and Boulder, CO. (OBBeC) - Agilent Technologies has announced that it has secured an exclusive license to Aktiv-Dry’s CAN-BD drying technology for nucleic acid active pharmaceutical ingredients (API’s).

Can-BD is a continuous drying technology that produces uniform particles of low moisture nucleic acids, under very mild conditions, in a fraction of the time required by current batch freeze-drying methods, claims the company. The closed nature of the drying and collection system also reduces the risk of product contamination. The new spray-drying technology is expected to significantly reduce capital requirements and labour costs associated with large-scale drying of therapeutic nucleic acids.

Agilent will present a poster on this technology entitled “CAN-BD: A Novel Drying Technology for Therapeutic Oligonucleotides” at the upcoming TIDES Conference at Red Rock Resort and Spa in Las Vegas, Nev., May 19-21.